Heterologous desensitization of bombesin- and vasopressin-stimulated phospholipase D activity in Swiss 3T3 fibroblasts  by Briscoe, Celia P. & Wakelam, Michael J.O.
FEBS Letters 361 (1995) 162 166 FEBS 15220 
Heterologous desensitization of bombesin- and vasopressin-stimulated 
phospholipase D activity in Swiss 3T3 fibroblasts 
Celia E Briscoe**, Michael J.O. Wakelam* 
University of Birmingham Institute for Cancer Studies, Clinical Research Block, Queen Elizabeth Hospital, Birmingham, B15 2TH, 
and Department ofBiochemistry, University of Glasgow, Glasgow, GI2 8QQ, UK 
Received 20 January 1995 
Abstract Bombesin- and vasopressin-stimulated phospholipase 
D (PLD) activities are rapidly desensitized in 3T3 cells, in addi- 
tion both agonists are subject to heterologous desensitization. 
Binding studies showed that homologous desensitization was 
partly a result of loss of cell surface receptors, whilst heterologous 
desensitization was independent of receptor changes. Pretreat- 
ment with either agonist reduced subsequent GTPyS-stimulated 
PLD activity by 50% whereas a pretreatment with GTPyS did 
not attenuate the response, suggesting that the G-protein or 
downstream effector systems were affected by receptor activation 
resulting in desensitization. The desensitization of receptor-stim- 
ulated PLD activation provides support for the phospholipase 
functioning in a key signalling pathway. 
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1. Introduction 
Desensitisation is a key characteristic of second-messenger 
pathways and is represented by diminished responsiveness to 
persistent agonist stimulation. A notable feature of Ptdlns- 
PLC-linked receptors i the very rapid homologous desensitisa- 
tion to agonist (reviewed in [1]), characterised by a decrease in 
the rate of phosphoinositide hydrolysis, the extent of which is 
receptor specific [2,3]. Homologous desensitisation f bomb- 
esin-stimulated Ins(1,4,5)P3 production in Swiss 3T3 cells is 
rapid, reversible, dose dependent and PKC-independent [4]. In 
addition heterologous desensitisation f both vasopressin and 
bombesin-stimulated Ins(1,4,5)P3 has been detected (unpub- 
lished results). 
Further to the well characterised hydrolysis of PtdlnsP2 by 
phospholipase C, the phospholipase D (PLD) catalysed hydrol- 
ysis of phosphatidylcholine  response to a range of agonists 
has been reported [5]. It remains incompletely defined as to how 
an occupied cell surface receptor stimulates PLD activity, but 
activation has been proposed to be downstream of protein 
kinase C activity, tyrosine kinase activity or changes in calcium 
concentration, a role for the small molecular weight G-protein 
ARF in directly regulating PLD has also been proposed [6,7]. 
Bombesin-stimulated PLD activity in Swiss 3T3 cells as deter- 
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mined by [3H]PtdBut generation is inhibited by 50-70% by the 
selective PKC inhibitor Ro-31-8220 [8] which would suggest 
that activation is predominantly downstream of PtdlnsP2 hy- 
drolysis. We have previously shown that pretreatment of Swiss 
3T3 cells with vasopressin or bombesin completely attenuated 
the [3H]PtdBut generation i response to a subsequent stimula- 
tion with the same agonist [9]. This homologous desensitisation 
was found to be PKC-independent and rapidly reversible ven 
in the continual presence of agonist. At least some of the atten- 
uated response was thought o be due to the rapid loss in 
cell-surface receptor binding. The loss of cell-surface binding 
was subsequent to an internalisation f the receptor, with re- 
ceptor ecycling to the cell surface occurring over a similar time 
course to resensitization f agonist-stimulated PLD activity. 
However, resensitization f agonist-stimulated PLD activity 
was less than the recovery of cell surface receptor binding 
suggesting that downstream signalling components were also 
affected. Furthermore the IC50 for bombesin-mediated homolo- 
gous desensitisation f stimulated PLD activity was 10-fold 
lower than other bombesin-receptor linked responses. In order 
to investigate the effect of a short agonist pretreatment on 
downstream effector mechanisms the heterologous nature of 
desensitisation was therefore determined in both intact and 
permeabilised 3T3 cells. 
2. Materials and methods 
2.1. Cell culture 
Swiss 3T3 cells were maintained inDulbecco's modified Eagles' me- 
dium (DMEM) containing 10% (v/v) newborn calf serum, 27 mg glu- 
tamine/ml and penicillin/streptomycin (250 units/ml and 250 mg/ml, 
respectively) at 37°C in a humidified atmosphere of air/CO2 (19: 1). 
Cells were grown to confluency and quiescence byserum depletion i  
2% (v/v) calf serum for 24 h prior to experiment. For labelling studies 
([9,10(n)-3H]palmitic acid, 2/ICi in 0.5 ml) was included in the 2%- 
serum containing medium. 
2.2. Assay of PLD transphosphatidylation activity in whole cells 
Quiescent Swiss 3T3 cells labelled with [3H]palmitic a id were washed 
in 0.5 ml Hanks buffered saline solution, pH 7.4, containing 10 mM- 
glucose, 1% (w/v) BSA and 20 mM HEPES (HHBG) for 20 min at 37 ° C 
prior to incubation for a further 5 min in 0.5 ml of HHBG containing 
30 mM butan-l-ol (0.3%, v/v). Incubations were commenced byreplac- 
ing the medium with 0.2 ml of HHBG/butan-l-ol and the stimulant at 
the concentrations and times indicated. Incubations were terminated by 
removal of the medium and addition of ice-cold methanol. After extrac- 
tion of lipids in chloroform, [3H]phosphatidylbutanol was separated by 
t.l.c, as described previously [8]. 
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2.3. Cell permeabilisation 
Quiescent Swiss 3T3 cells grown in 24-well plates and labelled with 
[3H]palmitic acid as described above for the PLD assay in intact cells, 
were washed in 0.5 ml HHBG for 20 min at 37°C prior to addition for 
5 min of streptolysin O (0.6 i.u./ml final) in permeabilisation buffer 
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containing 20 mM HEPES, pH 7.2, 120 mM KC1, 8.49 mM MgCI, 
61//M CaCI, 2 mM KH2PO4, 0.1 mM EGTA, 0.1% BSA and 2.5 mM 
ATP (150 nM Ca 2* final) as previously described [10]. This was fol- 
lowed by washing twice with 150/tl of permeabilisation buffer over 
10-15 s and stimulation with 150/11 of the test reagent in permeabilisa- 
tion buffer containing 30 mM butanol at the concentrations and times 
indicated. Incubations were terminated by direct addition of 0.5 rnl 
methanol and lipids extracted in chloroform. The lipid extracts were 
tilen treated exactly as described for the PLD transphosphatidylation 
~ ~say in intact cells, 
; 4. Binding of[3H]AVP and [3H]AVP antagonist o Swiss 3T3 cells 
Binding to intact cells was performed as described [11]. Quiescent 
c,:lls were washed three times over 20 min at 37°C in DMEM supple- 
vlented with glutamine, 10 mM HEPES, pH 7.4, and 0.2% (w/v) bovine 
~,~rum albumin. Pretreatments were performed at 37°C for the times 
i ~dicated with the test reagent at the required concentration in DMEM 
,~applemented with glutamine, 10 mM HEPES, pH 7.4, 0.05% (w/v) 
bovine serum albumin, 10 mM glucose and 2 mM bacitracin. After 
, ,ashing incubations were commenced by replacing the medium for the 
t~mes indicated with incubation buffer containing [3H]vasopressin an- 
lagonist LB-mercapto-fl-~8-cyclopenta-methylenepropionyll,0-Et-Tyr 2, 
\'ala,ArgS]vasopressin ([3H]AVP antagonist) or [8-Arginine][Phe-3,4,5- 
.~I(n)]vasopressin ([3H]AVP) at the required concentration. The me- 
tium was then removed and the cells washed 4 times with ice-cold 
,~)MEM supplemented with glutamine, 10 mM HEPES, pH 7.4, and 
q.l% (w/v) bovine serum albumin, solubilised for 30 rain at room 
• .'mperature in 0.5 M NaOH, 1% (w/v) SDS and 10 mM HEPES, 
~,eutralised with 0.5 M HC1 and the radioactivity determined by liquid- 
- cintillation counting. Non-specific binding was determined as the radi- 
, ligand not displaced by a 200-fold excess of unlabelled antagonist or 
. gonist as appropriate. Cell number was determined using one well per 
!,late which was treated in the same way, except hat no agonist pre- 
reatment or radiolabel was added and after the final wash, cells were 
: emoved from the well with trypsin and counted using a haemocytom- 
ter. 
~. Results and discussion 
The nature of agonist-desensitised PLD activity was investi- 
gated, by pretreating cells with maximal concentrations of ei- 
ther bombesin or vasopressin for 1 min in the absence of bu- 
tanol, washing the cells briefly, then stimulating with the other 
agonist for 1 min in the presence of butanol. Fig. 1 shows that 
pretreatment with 100 nM bombesin or vasopressin completely 
prevented a subsequent generation of [3H]PtdBut, in response 
to the same agonist as previously reported [9]. In addition when 
the alternative agonist was used for the stimulation of PLD 
activity a reduction in that detected in the control cells was also 
observed, however, in contrast o homologous desensitization, 
between 2(~30% of the agonist-stimulated [3H]PtdBut gener- 
ated attained in the absence of any pretreatment remained. 
Thus agonist-stimulated PLD activation can be desensitized in
a heterologous as well as a homologous manner. 
Since the homologous desensitization of bombesin-stimu- 
lated PLD activity is in part mediated through a reduction in 
cell surface receptors, vasopressin receptor number was exam- 
ined. Firstly, the vasopressin receptors upon Swiss 3T3 cells 
were characterised, the number of vasopressin receptors per cell 
was determined by measuring the specific binding of a [3H]vaso- 
pressin antagonist at 4°C as a function of ligand concentration. 
Equilibrium binding of the [3H]vasopressin antagonist was 
reached after 1 h and Scatchard analysis generated a K d of 2.5 
nM and a Bma x of approximately 50,000 receptors per cell (Fig. 
2). This value is similar to that reported by Collins and Rozen- 
gurt [12]. Table 1 shows that a 1 min pretreatment with a 
maximal dose of bombesin at 37°C had no effect upon the 
binding of either [3H]AVP or the [3H]AVP antagonist at 4 ° C, 
whereas a 1 min pretreatment with unlabelled AVP at 37°C 
reduced subsequent [3H]vasopressin antagonist binding at 4°C 
by 70%. This suggested that, as we have previously reported for 
bombesin, homologous desensitization of AVP-stimulated 
PLD activity was due to a reduction in cell surface vasopressin 
receptor number. In contrast heterologous desensitisation was 
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!~ig. 1. Heterologous desensitisation f agonist-stimulated PLD activity. [3H]Palmitate-labelled cells were pretreated for 1 min with buffer, 100 nM 
msopressin or 100 nM bombesin in the absence of butanol, then washed for 3 x 30 s with buffer. Cells were stimulated for 1 min in the presence 
,)f 30 mM butanol with buffer, 100 nM bombesin or 100 nM AVE Incubations were terminated with ice-cold methanol, chloroform extracts prepared 
and the generation of [3H]PtdBut quantified. Results are expressed as radioactivity in [3H]PtdBut (mean d.p.m. + S.D., n -- 3) and are from a single 
~xperiment typical of three. -(pt), cells pretreated with buffer; -(st), cells stimulated with buffer + butanol; BOM (pt), cells pretreated with 100 nM 
bombesin; BOM (st), cells stimulated with 100 nM bombesin + butanol; VP (pt), cells pretreated with 100 nM AVP; VP (st), cells stimulated with 
t00 nM AVP + butanol. 
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Fig. 2. Scatchard analysis of[3H]AVP antagonist binding to intact Swiss 
3T3 cells at 4°C. Swiss 3T3 cells were grown in 6-well plates, washed 
and incubated with [3H]AVP antagonist a concentrations i dicated for 
1 h at 4°C, cell associated radioactivity was then determined as in 
section 2. Non-specific binding at each concentration was determined 
in the presence of a 200-fold excess of AVP antagonist and was sub- 
tracted from total binding to give the specific binding shown. Results 
are expressed as: (A) a saturation isotherm of total (©), specific (o) and 
non-specific (zx) binding, of [3H]AVP antagonist in fmol/well, (B) the 
derived Scatchard plot where, Bm~x -- 24 fmol, Kd --- 2.5 nM. Each point 
was performed in duplicate and results were taken from a single exper- 
iment representative of three. The number of cells per well was approx- 
imately 2.8 x 105. 
not a consequence of a reduction in cell surface receptors. The 
heterologous desensitization f bombesin-stimulated PLD ac- 
tivity was also not due to a reduction in receptor number since 
a 1 min pretreatment with AVP was without effect upon the 
binding of [125i]gastrin releasing peptide (which is an agonist for 
bombesin receptors) over 1 min at 37°C (results not shown). 
Indeed prolonged AVP pretreatment has been reported not to 
alter the number, affinity or internalisation capacity of bomb- 
esin-receptors in Swiss 3T3 cells [13]. 
Bombesin and vasopressin receptors in Swiss 3T3 cells cou- 
ple through the pertussis-toxin i sensitive G-protein, Gq to the 
activation of phospholipase Cfll. We have previously reported 
that bombesin-stimulated PLD activity was also regulated by 
guanine-nucleotides, though whether a G-protein other than 
Gq was involved was not determined [14]. However there is 
evidence that the small molecular weight G-proteins ARF  [6,7] 
and rho [15] can regulate activity. Experiments were thus per- 
formed to investigate whether a short agonist exposure could 
affect the stimulation of PLD activity through G-protein acti- 
vation alone. Permeabilised cells were pretreated for 1 min with 
bombesin (Fig. 3A), or vasopressin (Fig. 3B), washed briefly 
and stimulated for 5 min with 30/.tM GTPyS. Both 3 nM 
bombesin and 30 nM vasopressin partially reduced the subse- 
quent generation of [3H]PtdBut in response to GTPyS in the 
presence of butanol, to approximately 50% of that attained in 
the absence of pretreatment. Fig. 3A also shows that a 1 min 
pretreatment with 30 pM GTPyS did not reduce subsequent 
GTPyS stimulated [3H]PtdBut accumulation. This suggested 
that agonist-induced desensitisation f PLD activity is not due 
solely to receptor/G-protein u coupling which has been pro- 
posed to be the site of PMA-mediated inhibition of bombesin- 
stimulated Ins(l,4,5)P3 generation in Swiss 3T3 cells [16]. 
Therefore a component of the signalling pathway at, or down- 
stream of the G-protein is also affected. 
The agonist-induced.reduction in G-protein regulated PLD 
activity may account for the attenuation of stimulated PLD 
activity observed in response to a second agonist (Fig. 1). This 
may occur if the receptors for both agonists use the same pool 
of G-proteins to activate PLD as proposed for the a :adreno-  
ceptor and the AVP receptor in hepatocytes [17]. The finding 
that GTPyS pretreatment of cells did not decrease a subsequent 
GTPyS-stimulation of PLD activity suggested that activation 
of the G-protein itself, is insufficient for desensitisation but that 
receptor activation and coupling to the G-protein is essential. 
This contrasts with desensitisation f the fl-adrenergic receptor 
where stimulation of adenylyl cyclase through the activation of 
Gs was not affected espite loss of responsiveness to the agonist 
and alterations in the function of Gs did not affect desensitisa- 
tion offl-adrenergic receptors [18]. 
As agonist-stimulated PLD activity is reduced by 50-70% 
following pretreatment with the protein kinase C inhibitor Ro- 
31-8220 [8] and heterologous desensitisation f stimulated PLD 
activity resulted in such a large attenuation of the response, it 
proved impossible to demonstrate the involvement of PKC in 
Table 1 
Effect of a 1 min pretreatment at 37°C with 30 nM vasopressin or 100 
nM bombesin on [3H]AVP antagonist binding 
Treatment Specific [3H]AVP % of [3H]AVP 
antagonist bound antagonist bound 
(fmol/well) in the absence of 
pretreatment 
No pretreatment, 
0 min wash 15.9 + 0.6 100 + 4 
1 rain AYP pretreatment, 
0 min wash 5.2 + 0.1 33 + 1 
1 min born pretreatment, 
0 rain wash 14.9 + 1.7 94 + 9 
Quiescent cells were washed and pretreated for 1 min with 30 nM AVE 
100 nM bombesin or incubation buffer alone at 37°C. After washing 
the binding of [3H]AVP antagonist was determined as described in 
section 2. Non-specific binding was determined ateach time point, by 
including a200-fold excess of unlabelled AVP antagonist (1gM) in the 
binding medium. Results are expressed as: specific bound [3H]AVP 
antagonist in fmol/well, after subtracting non-specific binding 
(mean + S.D., n = 2); also as % of [3H]AVP antagonist bound, where 
incubation buffer was used during the pretreatment period 
(mean _+ S.D.%, n = 2). Results are taken from a single experiment 
representative of two. The number of cells per well was approximately 
1.8 x 105. 
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Fig. 3. Effect of agonist pretreatment onGTPTS-stimulated PLD activity. [3H]Palmitate-labelled c lls were permeabilised with streptolysin-O (0.6 
U- ml-X), then pretreated for 1 min in the absence of butanol, with buffer or; (A) 3 nM bombesin or GTPyS; (B) 30 nM vasopressin. Cells were washed 
,timulated for 5 rain with vehicle or 30 pM GTPyS in the presence of 30 mM butanol and the generation of [3H]PtdBut determined. Results are 
~xpressed as radioactivity in [3H]PtdBut (mean d.p.m. _+ S.D., n = 3) from a single experiment representative of three. -(pt), cells pretreated with 
!mffer; -(st), cells stimulated with buffer + butanol; BOM (pt), cells pretreated with 100 nM bombesin; VP (pt), cells pretreated with 100 nM 
:asopressin; GTP[S] (pt), cells pretreated with GTPyS; GTP[S] (st), cells stimulated with GTPTS + butanol. 
he  phenomenon. However we have previously shown that a 
l min pretreatment with bombesin had no effect on a subse- 
quent PMA stimulation of PLD activity [9], suggesting that 
tgonist pretreatment of cells did not affect the stimulation of 
PLD induced by the activation of PKC. 
A number of studies have suggested a role for an increase in 
Ca2+]i in the regulation of agonist-stimulated PLD activity. In 
relation to this carbachol-mediated desensitisation f ~-throm- 
oin-stimulated PLD activity in Chinese hamster lung fibro- 
blasts has been proposed to be due to the depletion of intracel- 
lular Ca 2+ stores [19]. Heterologous desensitisation f agonist- 
~timulated Ca z* mobilisation in astrocytoma cells [20] and in 
bombesin-stimulated human small cell lung cancer cell lines [21] 
and has been suggested to be due to emptying of the 
Ins(1,4,5)P 3 sensitive Ca 2+ pools. It was therefore considered 
possible that changes in [Ca2+]i may be involved in heterologous 
desensitization f PLD activity in Swiss 3T3 cells. 
Arguing against a role for Ca 2+ are the observations that 
changes in [Ca2+]i play only a minimal role in bombesin-stimu- 
lated PLD activity [8] and that treatment of cells with the Ca 2+ 
ionophore A23187 which elevates [Ca2÷]i induces a small desen- 
sitization of bombesin-stimulated PLD [9]. Further in the ex- 
periments examining the effect of GTP7S upon PLD activity 
in permeabilised cells, in which a desensitization was or was not 
observed epending upon pretreatment, a Ca2+-EGTA buffer 
which maintained the [Ca z÷] at 150 nM was utilised. 
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Since neither effects upon [Ca2+]~ or PKC activity appear to 
be involved in heterologous desensitization f agonist-stimu- 
lated PLD activity, the involvement of other second messengers 
must be considered. Bombesin is among several peptide ag- 
onists known to induce the rapid tyrosine phosphorylation f
a number of proteins in Swiss 3T3 cells [14,22]. The finding that 
genistein partially inhibited bombesin-stimulated PLD activity 
suggested that tyrosine kinases may be involved in the PKC- 
independent pathway of agonist-stimulated [3H]PtdBut genera- 
tion. It is conceivable that phosphorylation on tyrosine of a 
component of the signalling pathway downstream of the recep- 
tor/G-protein interaction may prevent the full activation of 
PLD by another agonist. Furthermore phosphorylation by a 
serine/threonine kinase such as MAP kinase which is activated 
by mechanisms involving tyrosine phosphorylation could also 
be involved. The product of PLD activation, phosphatidate 
(PtdOH) might also exert a regulatory feedback effect. PtdOH 
has been reported to have multiple second messenger effects 
(reviewed in [23]) including inhibition of adenylyl cyclase, acti- 
vation of phosphatidate-dependent kinases [24] and regulation 
of small molecular weight G-protein guanine nucleotide state 
[25]. Full elucidation of the mechanism underlying the loss of 
stimulated PLD activity in a homologous or heterologous man- 
ner awaits purification of the enzyme and thus reconstitution 
with the possible components of the stimulatory pathway. Nev- 
ertheless the identification of both homologous and heterolo- 
gous desensitization pathways in the regulation ofagonist-stim- 
ulated PLD activity emphasises the potential importance of this 
phospholipase asa second messenger generating enzyme. 
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